Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629946 | 0.68 | CYP2C19 (0.57) | DPP4F2CYP2C19SCN4ATAAR1 | |
| SCHEMBL898390 | 0.68 | CYP2C19 (0.57) | DPP4F2CYP2C19SCN4ATAAR1 | |
| SCHEMBL7406881 | 0.68 | CYP2C19 (0.57) | DPP4F2CYP2C19SCN4ATAAR1 | |
| Hydrochloric Acid SCHEMBL25188226 | 0.67 | CYP2C19 (0.55) | DPP4F2CYP2C19SCN4ATAAR1 | |
| Hydrochloric Acid SCHEMBL250191 | 0.67 | CYP2C19 (0.55) | DPP4F2CYP2C19SCN4ATAAR1 | |
| Hydrochloric Acid SCHEMBL31471464 | 0.67 | CYP2C19 (0.55) | DPP4F2CYP2C19SCN4ATAAR1 | |
| SCHEMBL8050506 | 0.65 | CYP2C19 (0.44) | DPP4F2CYP2C19SCN4ATAAR1 | |
| SCHEMBL1678152 | 0.65 | DPP4 (0.52) | DPP4F2CYP2C19TAAR1HTR2A | |
| SCHEMBL8067055 | 0.65 | CYP2C19 (0.44) | DPP4F2CYP2C19SCN4ATAAR1 | |
| SCHEMBL4785073 | 0.65 | CYP2C19 (0.44) | DPP4F2CYP2C19SCN4ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562640-B1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | UNIV MCMASTER (CA) | 2012-12-05 | — | — | EP | disclosed |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | MCMASTER UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-7335347-B2 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2008-02-26 | — | — | US | disclosed |
| EP-1562640-A2 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | Molecular Insight Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2004-12-23 | — | — | US | disclosed |
| WO-2004035744-A2 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | BIOSTREAM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | PAICS, PFAS, NPEPPS | DPP4 1409/4885F2 2484/4885CYP2C19 1603/4885 |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | PAICS, PFAS, NPEPPS | DPP4 1409/4885F2 2484/4885CYP2C19 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.